EA201391382A1 - Способы диагностики и лечения с применением библиотеки лигандов - Google Patents

Способы диагностики и лечения с применением библиотеки лигандов

Info

Publication number
EA201391382A1
EA201391382A1 EA201391382A EA201391382A EA201391382A1 EA 201391382 A1 EA201391382 A1 EA 201391382A1 EA 201391382 A EA201391382 A EA 201391382A EA 201391382 A EA201391382 A EA 201391382A EA 201391382 A1 EA201391382 A1 EA 201391382A1
Authority
EA
Eurasian Patent Office
Prior art keywords
library
treatment
methods
drug
relates
Prior art date
Application number
EA201391382A
Other languages
English (en)
Other versions
EA037648B1 (ru
Inventor
Муралидхар Редди Моола
Джессика Шилке
Original Assignee
ОПКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОПКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical ОПКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA201391382A1 publication Critical patent/EA201391382A1/ru
Publication of EA037648B1 publication Critical patent/EA037648B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C40B20/08—Direct analysis of the library members per se by physical methods, e.g. spectroscopy
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/12—Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)

Abstract

Настоящее изобретение относится к способам диагностики и лечения с применением библиотеки лигандов. В частности, настоящее изобретение относится к применению библиотеки лигандов для диагностики или детектирования реакции, вызванной лекарственным средством, включая нежелательные реакции на лекарство, побочные эффекты, устойчивость к лекарству и терапевтическую эффективность. Настоящее изобретение также относится к идентификации биомаркеров, ассоциированных с вызванной лекарственным средством реакцией, и обеспечению персонализированного лечения.
EA201391382A 2011-03-24 2012-03-23 Способ диагностики с использованием библиотеки пептоидных лигандов EA037648B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161467256P 2011-03-24 2011-03-24
US201161491717P 2011-05-31 2011-05-31
US201261583881P 2012-01-06 2012-01-06
PCT/US2012/030223 WO2012129457A2 (en) 2011-03-24 2012-03-23 Diagnostic and treatment methods using a ligand library

Publications (2)

Publication Number Publication Date
EA201391382A1 true EA201391382A1 (ru) 2014-09-30
EA037648B1 EA037648B1 (ru) 2021-04-27

Family

ID=46880042

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201391378A EA032582B1 (ru) 2011-03-24 2012-03-22 Библиотека случайных пептоидных лигандов для скрининга биологической жидкости
EA201391382A EA037648B1 (ru) 2011-03-24 2012-03-23 Способ диагностики с использованием библиотеки пептоидных лигандов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201391378A EA032582B1 (ru) 2011-03-24 2012-03-22 Библиотека случайных пептоидных лигандов для скрининга биологической жидкости

Country Status (14)

Country Link
US (2) US9804168B2 (ru)
EP (2) EP2688911B1 (ru)
JP (2) JP6153921B2 (ru)
KR (2) KR20140027174A (ru)
CN (2) CN103748270B (ru)
AU (2) AU2012230880B2 (ru)
BR (2) BR112013024453A2 (ru)
CL (2) CL2013002732A1 (ru)
CO (2) CO6870029A2 (ru)
EA (2) EA032582B1 (ru)
HK (1) HK1197088A1 (ru)
MX (2) MX2013011000A (ru)
TW (2) TWI630389B (ru)
WO (2) WO2012129423A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014019501A1 (zh) * 2012-08-03 2014-02-06 天津工业大学 一种具有锂同位素分离效应的苯并冠醚接枝聚合物及其制备方法
US10677795B2 (en) 2014-05-09 2020-06-09 Protagen Ag Marker sequences for the diagnosis and stratification of systemic sclerosis patients
WO2017015644A1 (en) * 2015-07-23 2017-01-26 University Of Houston System Cancer specific lipid targeted peptidomimetics
JP7011830B2 (ja) 2015-10-14 2022-01-27 エックス－サーマ インコーポレイテッド 氷晶形成を低減するための組成物および方法
EP3426672B1 (en) 2016-03-09 2021-09-01 Mike-Ann, LLC Peptoid affinity ligands
EP3433262A4 (en) 2016-03-25 2019-11-20 Muralidhar Reddy Moola COMBINATORY SYNTHESIS AND DEVELOPMENT OF BIOMARKERS
CN106854233B (zh) * 2017-03-03 2020-07-17 国家纳米科学中心 一种类肽及其制备方法和应用
WO2023014666A1 (en) * 2021-08-04 2023-02-09 University Of Houston System Vimentin targeted peptoids for early diagnosis and treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834318A (en) * 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US20040241759A1 (en) 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
WO2000009464A1 (en) 1998-08-17 2000-02-24 Phylos, Inc. Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
WO2001040264A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
US7153682B2 (en) 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
JP4343534B2 (ja) * 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
TW573125B (en) 2001-08-29 2004-01-21 Combinatorx Inc A screening system for identifying drug-drug interactions and methods of use thereof
US20060275829A1 (en) 2002-04-15 2006-12-07 Hammond David J Combinatorial library for proteomic investigations
US20060275753A1 (en) 2002-04-15 2006-12-07 Hammond David J Recovery of analytes using combinatorial libraries
AU2003299518A1 (en) * 2002-05-17 2004-05-13 Slanetz, Alfred E. Process for determining target function and identifying drug leads
EP1521841B1 (en) 2002-07-11 2010-04-14 The American National Red Cross Method for identifying individual active entities from complex mixtures
JP5072901B2 (ja) * 2003-02-24 2012-11-14 譲治 稲澤 薬剤耐性マーカーおよびその利用
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
CA2521826C (en) * 2003-04-11 2013-08-06 Jennifer L. Reed Recombinant il-9 antibodies and uses thereof
CN1809383A (zh) * 2003-04-11 2006-07-26 免疫医疗公司 重组il－9抗体及其用途
EP1635693A2 (en) * 2003-05-23 2006-03-22 Board Of Regents, The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
EP1644536A4 (en) * 2003-07-08 2008-07-23 Univ California GENETIC MARKERS FOR RESPONSE TO ATYPIC ANTIPSYCHOTICS AND ANTIDEPRESSIVA AND METHOD FOR USE THEREOF
AU2003287040A1 (en) * 2003-10-08 2005-05-26 The Regents Of The University Of California Screening combinatorial bead libraries for cancer ligands
JP2006025069A (ja) * 2004-07-07 2006-01-26 Hitachi Ltd 機器制御装置及び電気機器
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
US20060199206A1 (en) * 2005-03-01 2006-09-07 Hong Wang Method for identifying skin care composition-resistant skin-binding peptides
US20070003954A1 (en) 2005-05-12 2007-01-04 The Board Of Regents Of The University Of Texas System Protein and antibody profiling using small molecule microarrays
US8119572B2 (en) 2005-10-24 2012-02-21 Wisconsin Alumni Research Foundation Methods for determining protein binding specificity using peptide libraries
US20070111322A1 (en) * 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
WO2007137405A1 (en) * 2006-05-25 2007-12-06 University Health Network Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis
US7875431B2 (en) * 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
US20100266610A1 (en) * 2007-05-03 2010-10-21 Medimmune, Llc Auto-antibody markers of autoimmune disease
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
TWM333876U (en) 2007-09-21 2008-06-11 Jer-Yuan Jang Device of auxiliary bathing tool
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2010014651A1 (en) * 2008-07-31 2010-02-04 The Brigham And Women's Hospital, Inc. Pharmacogenetic markers for susceptibility to drug-induced pancreatic toxicity
JP2010071744A (ja) * 2008-09-17 2010-04-02 Sekisui Chem Co Ltd 化合物のスクリーニング方法、並びに、スクリーニング用キット
EP2435827A1 (en) 2009-05-29 2012-04-04 The Board of Regents of The University of Texas System Peptoid ligands for isolation and treatment of autoimmune t-cells
AU2010256880B2 (en) * 2009-06-02 2015-01-22 Opko Health, Inc. Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
JP2011004743A (ja) * 2009-06-26 2011-01-13 Dna Chip Research Inc 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
WO2011044253A1 (en) * 2009-10-06 2011-04-14 Wisconsin Alumni Research Foundation Metabolic biomarkers of drug-induced cardiotoxicity
US8759259B2 (en) * 2009-10-16 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for producing cyclic peptoid libraries

Also Published As

Publication number Publication date
BR112013024453A2 (pt) 2016-09-06
MX351228B (es) 2017-09-06
EA201391378A1 (ru) 2014-09-30
AU2012230880B2 (en) 2017-04-13
US20120270741A1 (en) 2012-10-25
MX2013011000A (es) 2014-03-27
WO2012129457A3 (en) 2013-12-12
KR20140027174A (ko) 2014-03-06
EP2688911A4 (en) 2015-08-26
EP2689053A2 (en) 2014-01-29
CL2013002731A1 (es) 2014-04-04
AU2012230818A1 (en) 2013-10-24
JP6153921B2 (ja) 2017-06-28
JP6412798B2 (ja) 2018-10-24
TWI630389B (zh) 2018-07-21
EA037648B1 (ru) 2021-04-27
CL2013002732A1 (es) 2014-04-04
WO2012129457A2 (en) 2012-09-27
JP2014515739A (ja) 2014-07-03
EP2689053B1 (en) 2018-11-14
CN103562444B (zh) 2017-08-25
CN103748270B (zh) 2018-04-24
MX2013010999A (es) 2014-03-27
CN103748270A (zh) 2014-04-23
AU2012230818B2 (en) 2016-12-08
EP2688911B1 (en) 2017-08-02
WO2012129423A2 (en) 2012-09-27
TW201300591A (zh) 2013-01-01
BR112013024454A2 (pt) 2017-09-19
TW201310033A (zh) 2013-03-01
JP2014510919A (ja) 2014-05-01
US9804168B2 (en) 2017-10-31
AU2012230880A1 (en) 2013-10-24
HK1197088A1 (en) 2015-01-02
WO2012129423A3 (en) 2012-11-22
CO6870002A2 (es) 2014-02-20
CN103562444A (zh) 2014-02-05
EA032582B1 (ru) 2019-06-28
EP2688911A2 (en) 2014-01-29
KR20140029411A (ko) 2014-03-10
US20120269799A1 (en) 2012-10-25
EP2689053A4 (en) 2015-05-06
CO6870029A2 (es) 2014-02-20

Similar Documents

Publication Publication Date Title
EA201391382A1 (ru) Способы диагностики и лечения с применением библиотеки лигандов
MX347853B (es) Ensayo cuantitativo rapido para medir la funcion del regulador de conductancia de transmembrana de fibrosis quistica (cftr) en un molde de cultivo intestinal primario.
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112015028253A2 (pt) biomarcadores relacionados à função renal e métodos para utilização dos mesmos
MA34091B1 (fr) Anticorps anti-cd40
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
HK1201577A1 (en) Point-of care immunoassay for quantitative small analyte detection
BR112014009643A2 (pt) métodos para diagnosticar ou detectar neoplasia colorretal em um sujeito humano, biomarcador para progressão de doença e kits para um diagnóstico de neoplasia colorretal
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
EP3004394A4 (en) ASSAYS, METHODS AND KITS FOR ANALYZING SENSITIVITY AND RESISTANCE TO ANTICANCER DRUGS, GIVING PROGNOSTIC CANCER PATIENT, AND PERSONALIZED THERAPEUTIC STRATEGIES
WO2014041185A3 (en) Colon cancer diagnostic method and means
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
GB2519907A (en) Systems and methods for diagnosing strokes
WO2014106001A3 (en) Dual specific binding proteins having a receptor sequence
EP2723866A4 (en) METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES
WO2014158287A3 (en) A method for improving disease diagnosis using measured analytes
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
MX359328B (es) Metodo para el diagnostico de enfermedad de niemann-pick.
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
WO2013063412A3 (en) Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions